The earnings call reflects a positive sentiment with the successful launch and strong performance of EMROSI, increased gross margins, and expanded payer access. However, these positive outcomes are slightly offset by declines in Accutane revenue, increased SG&A expenses, and a higher net loss.

Company Guidance

During Journey Medical's second-quarter 2025 conference call, the company reported solid financial performance, driven by the successful launch of EMROSI, an oral rosacea treatment. Key metrics revealed that net product revenue reached $15 million, with EMROSI contributing approximately $2.8 million to this figure. Despite a decline in Accutane sales due to generic competition, the company’s gross margin improved to 67% from 61% in the prior year. The call highlighted that EMROSI prescriptions surpassed 12,800 by the end of July, achieving over 10% share of new prescription demand among dermatologists. Additionally, payer access for EMROSI expanded significantly, covering approximately 65% of commercial lives, up from 30% in May. Journey Medical maintained a stable cash position of $20.3 million, reflecting minimal cash burn for the year. The company expressed confidence in sustaining momentum, with plans to further expand prescriber base, increase prescription volume, and enhance profitability.

Successful Launch of EMROSI

The second quarter of 2025 marks the first full quarter since the introduction of EMROSI, generating $2.8 million in sales and showing strong initial uptake with over 12,800 prescriptions.

Increase in Gross Margin

Gross margin increased to 67% for the second quarter of 2025 from 61% in the prior period, driven by product sales mix including EMROSI and Accutane.

Expanded Payer Access for EMROSI

Payer access for EMROSI increased from 30% of commercial lives in May to approximately 65% in July, covering over 100 million lives.

Recognition and Visibility

Journey Medical's stock was added to the small-cap Russell 2000 and broad market Russell 3000 indexes, and EMROSI was featured on Lifetime TV's The Balancing Act.

Journey Medical Corp (DERM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DERM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.03 / -	-0.12	―	―	―
Aug 12, 2025	2025 (Q2)	-0.10 / -0.16	-0.17	5.88% (+0.01)	―
May 14, 2025	2025 (Q1)	-0.24 / -0.18	-0.53	66.04% (+0.35)	―
Mar 26, 2025	2024 (Q4)	-0.20 / 0.10	-0.59	116.95% (+0.69)	―
Nov 12, 2024	2024 (Q3)	-0.17 / -0.12	0.99	-112.12% (-1.11)	―	―
Aug 12, 2024	2024 (Q2)	-0.14 / -0.17	-0.04	-325.00% (-0.13)	―
May 13, 2024	2024 (Q1)	-0.23 / -0.53	-0.57	7.02% (+0.04)	―
Mar 21, 2024	2023 (Q4)	-0.09 / -0.59	-0.6	1.67% (+0.01)	―
Nov 07, 2023	2023 (Q3)	-0.15 / 0.99	-0.23	530.43% (+1.22)	―
Aug 08, 2023	2023 (Q2)	-0.34 / -0.04	-0.15	73.33% (+0.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DERM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$8.54	$7.25	-15.11%
May 14, 2025	$5.97	$7.10	+18.93%
Mar 26, 2025	$6.14	$5.92	-3.58%
Nov 12, 2024	$5.45	$5.12	-6.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Journey Medical Corp (DERM) report earnings?

Journey Medical Corp (DERM) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is Journey Medical Corp (DERM) earnings time?

Journey Medical Corp (DERM) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DERM EPS forecast?

DERM EPS forecast for the fiscal quarter 2025 (Q3) is -0.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing